Abstract
Background
The benefit of adjuvant chemotherapy (AC) after pancreaticoduodenectomy (PD) for distal cholangiocarcinoma (DCC) remains controversial. The study aimed to evaluate the impact of AC after PD for DCC in a large multicentric cohort.
Methods
Patients from five French centers who underwent from PD for DCC between 2000 and 2015 and received AC (AC+ group) or surgery only (AC− group) were included in the analysis. Variables associated with AC administration were analyzed by univariate analysis. The Cox regression identified covariates associated with overall survival (OS) and disease-free survival (DFS). The AC+ cohort was matched to the AC− cohort (1:1) by a propensity score (PS) based on the likelihood of AC administration and independent factors associated with decreased OS and DFS.
Results
Of the 178 patients included, 56 (31.5%) received AC. In the whole cohort, no difference on OS and DFS between the AC+ and AC− groups was identified (P = 0.15 and P = 0.07, respectively). After PS matching, the AC+ group (n = 49) was comparable to the AC− group (n = 49) on factors associated with AC administration and on factors associated with a decreased survival in the large cohort. After matching, the medians of OS and DFS in the AC+ group and in the AC− group were comparable (26.27 vs 43.33 months, P = 0.34, and 15.47 vs. 14.70 months, P = 0.79, respectively).
Conclusion
Our study did not demonstrate a survival benefit of adjuvant chemotherapy (mostly base on gemcitabine regimen) for DCC after PD even after propensity score matching. New trial specially designed for DCC is urgently needed to improve survival after surgical resection.
Similar content being viewed by others
Abbreviations
- DCC:
-
Distal cholangiocarcinoma
- PD:
-
Pancreaticoduodenectomy
- AC:
-
Adjuvant chemotherapy
- RCT:
-
Randomized control trial
- ASA:
-
American Society of Anesthesiologists
- BMI:
-
Body mass index
- IQR:
-
Interquartile range
- OS:
-
Overall survival
- DFS:
-
Disease-free survival
- PDAC:
-
Pancreatic ductal adenocarcinoma
- ACRT:
-
Adjuvant chemoradiotherapy
References
Patel T (2011) Cholangiocarcinoma--controversies and challenges. Nat Rev Gastroenterol Hepatol 8:189–200. https://doi.org/10.1038/nrgastro.2011.20
Tol J A. MG, Brosens L a. A, van Dieren S, et al (2015) Impact of lymph node ratio on survival in patients with pancreatic and periampullary cancer. Br J Surg 102:237–245 . doi: https://doi.org/10.1002/bjs.9709
Horgan AM, Amir E, Walter T, Knox JJ (2012) Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis. J Clin Oncol 30:1934–1940. https://doi.org/10.1200/JCO.2011.40.5381
Murakami Y, Uemura K, Sudo T, Hashimoto Y, Nakashima A, Kondo N, Sakabe R, Ohge H, Sueda T (2010) Prognostic factors after surgical resection for intrahepatic, hilar, and distal cholangiocarcinoma. Ann Surg Oncol 18:651–658. https://doi.org/10.1245/s10434-010-1325-4
Courtin-Tanguy L, Rayar M, Bergeat D, Merdrignac A, Harnoy Y, Boudjema K, Meunier B, Sulpice L (2016) The true prognosis of resected distal cholangiocarcinoma: prognosis of distal cholangiocarcinoma. J Surg Oncol n/a–n/a 113:575–580. https://doi.org/10.1002/jso.24165
Oshiro Y (2013) Adjuvant surgery for advanced extrahepatic cholangiocarcinoma. World J Gastroenterol 19:6934–6938. https://doi.org/10.3748/wjg.v19.i40.6934
Wellner UF, Shen Y, Keck T, Jin WY, Xu Z (2016) The survival outcome and prognostic factors for distal cholangiocarcinoma following surgical resection: a meta-analysis for the 5-year survival. Surg Today 47:271–279. https://doi.org/10.1007/s00595-016-1362-0
Kim YS, Hwang IG, Park S-E, Go SI, Kang JH, Park I, Oh SY, Ji JH, Song HN, Park SH, Kim ST, Park JO (2016) Role of adjuvant therapy after R0 resection for patients with distal cholangiocarcinoma. Cancer Chemother Pharmacol 77:979–985. https://doi.org/10.1007/s00280-016-3014-x
Oettle H, Neuhaus P, Hochhaus A, Hartmann JT, Gellert K, Ridwelski K, Niedergethmann M, Zülke C, Fahlke J, Arning MB, Sinn M, Hinke A, Riess H (2013) Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA 310:1473–1481. https://doi.org/10.1001/jama.2013.279201
Yoshida T, Matsumoto T, Sasaki A, et al (2002) Prognostic factors after pancreatoduodenectomy with extended lymphadenectomy for distal bile duct cancer. Arch Surg Chic Ill 1960 137:69–73
Kiriyama M, Ebata T, Aoba T, Kaneoka Y, Arai T, Shimizu Y, Nagino M, of the Nagoya Surgical Oncology Group (2015) Prognostic impact of lymph node metastasis in distal cholangiocarcinoma. Br J Surg 102:399–406. https://doi.org/10.1002/bjs.9752
Hatzaras I, George N, Muscarella P, Melvin WS, Ellison EC, Bloomston M (2010) Predictors of survival in periampullary cancers following pancreaticoduodenectomy. Ann Surg Oncol 17:991–997. https://doi.org/10.1245/s10434-009-0883-9
Choi S-B, Kim K-S, Choi J-Y, Park SW, Choi JS, Lee WJ, Chung JB (2009) The prognosis and survival outcome of intrahepatic cholangiocarcinoma following surgical resection: association of lymph node metastasis and lymph node dissection with survival. Ann Surg Oncol 16:3048–3056. https://doi.org/10.1245/s10434-009-0631-1
Ruzzenente A, Fassan M, Conci S, Simbolo M, Lawlor RT, Pedrazzani C, Capelli P, D’Onofrio M, Iacono C, Scarpa A, Guglielmi A (2015) Cholangiocarcinoma heterogeneity revealed by multigene mutational profiling: clinical and prognostic relevance in surgically resected patients. Ann Surg Oncol 23:1699–1707. https://doi.org/10.1245/s10434-015-5046-6
Hughes MA, Frassica DA, Yeo CJ, Riall TS, Lillemoe KD, Cameron JL, Donehower RC, Laheru DA, Hruban RH, Abrams RA (2007) Adjuvant concurrent chemoradiation for adenocarcinoma of the distal common bile duct. Int J Radiat Oncol 68:178–182. https://doi.org/10.1016/j.ijrobp.2006.11.048
Kim BH, Kim K, Chie EK, Kwon J, Jang JY, Kim SW, Oh DY, Bang YJ (2016) Long-term outcome of distal cholangiocarcinoma after Pancreaticoduodenectomy followed by adjuvant chemoradiotherapy: a 15-year experience in a single institution. Cancer Res Treat 49:473–483. https://doi.org/10.4143/crt.2016.166
Qiao Q-L, Zhang T-P, Guo J-C, Zhan HX, Zhao JX, Liu YC, Wan YL, Leng XS, Zhao YP (2011) Prognostic factors after pancreatoduodenectomy for distal bile duct cancer. Am Surg 77:1445–1448
Choi SB, Park SW, Kim KS, Choi JS, Lee WJ (2009) The survival outcome and prognostic factors for middle and distal bile duct cancer following surgical resection. J Surg Oncol 99:335–342. https://doi.org/10.1002/jso.21238
Okusaka T, Nakachi K, Fukutomi A, Mizuno N, Ohkawa S, Funakoshi A, Nagino M, Kondo S, Nagaoka S, Funai J, Koshiji M, Nambu Y, Furuse J, Miyazaki M, Nimura Y (2010) Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br J Cancer 103:469–474. https://doi.org/10.1038/sj.bjc.6605779
Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, Roughton M, Bridgewater J, ABC-02 Trial Investigators (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362:1273–1281. https://doi.org/10.1056/NEJMoa0908721
Valle JW, Furuse J, Jitlal M, Beare S, Mizuno N, Wasan H, Bridgewater J, Okusaka T (2014) Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials. Ann Oncol Off J Eur Soc Med Oncol ESMO 25:391–398. https://doi.org/10.1093/annonc/mdt540
Marin JJ, Lozano E, Briz O et al (2015) Molecular bases of chemoresistance in cholangiocarcinoma. Curr Drug Targets
Primrose JN, Fox R, Palmer DH et al (2017) Adjuvant capecitabine for biliary tract cancer: the BILCAP randomized study. J Clin Oncol 35:4006–4006. https://doi.org/10.1200/JCO.2017.35.15_suppl.4006
Neoptolemos JP, Moore MJ, Cox TF, Valle JW, Palmer DH, McDonald AC, Carter R, Tebbutt NC, Dervenis C, Smith D, Glimelius B, Charnley RM, Lacaine F, Scarfe AG, Middleton MR, Anthoney A, Ghaneh P, Halloran CM, Lerch MM, Oláh A, Rawcliffe CL, Verbeke CS, Campbell F, Büchler MW, European Study Group for Pancreatic Cancer (2012) Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. JAMA 308:147–156. https://doi.org/10.1001/jama.2012.7352
Nakamura H, Arai Y, Totoki Y, Shirota T, Elzawahry A, Kato M, Hama N, Hosoda F, Urushidate T, Ohashi S, Hiraoka N, Ojima H, Shimada K, Okusaka T, Kosuge T, Miyagawa S, Shibata T (2015) Genomic spectra of biliary tract cancer. Nat Genet 47:1003–1010. https://doi.org/10.1038/ng.3375
Banales JM, Cardinale V, Carpino G, Marzioni M, Andersen JB, Invernizzi P, Lind GE, Folseraas T, Forbes SJ, Fouassier L, Geier A, Calvisi DF, Mertens JC, Trauner M, Benedetti A, Maroni L, Vaquero J, Macias RIR, Raggi C, Perugorria MJ, Gaudio E, Boberg KM, Marin JJG, Alvaro D (2016) Expert consensus document: cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European network for the study of cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol 13:261–280. https://doi.org/10.1038/nrgastro.2016.51
Suker M, Beumer BR, Sadot E, Marthey L, Faris JE, Mellon EA, el-Rayes BF, Wang-Gillam A, Lacy J, Hosein PJ, Moorcraft SY, Conroy T, Hohla F, Allen P, Taieb J, Hong TS, Shridhar R, Chau I, van Eijck CH, Koerkamp BG (2016) FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. Lancet Oncol 17:801–810. https://doi.org/10.1016/S1470-2045(16)00172-8
Schmuck RB, de Carvalho-Fischer CV, Neumann C, Pratschke J, Bahra M (2016) Distal bile duct carcinomas and pancreatic ductal adenocarcinomas: postulating a common tumor entity. Cancer Med 5:88–99. https://doi.org/10.1002/cam4.566
Author information
Authors and Affiliations
Contributions
Study concept and design: DB and LS. Acquisition of data: LCT, BD, ST, and NR. Analysis and interpretation of data: DB and LS. Drafting of the manuscript: DB and LS. Critical revision of the manuscript for important intellectual content: JRD, JYM, LS, NR, BD, and ST. Statistical analysis: DB and LCT.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval
For this type of study, formal consent is not required but the clinical data were retrospectively collected from a liver resection database and analyzed after institutional review board approval was obtained.
Electronic supplementary material
Fig. S1
Recurrences characteristics (DOCX 50 kb)
Rights and permissions
About this article
Cite this article
Bergeat, D., Turrini, O., Courtin-Tanguy, L. et al. Impact of adjuvant chemotherapy after pancreaticoduodenectomy for distal cholangiocarcinoma: a propensity score analysis from a French multicentric cohort. Langenbecks Arch Surg 403, 701–709 (2018). https://doi.org/10.1007/s00423-018-1702-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00423-018-1702-1